Human immunodeficiency virus 1 envelope glycoprotein gp120 V3 glycan supersite

The Human immunodeficiency virus 1 (HIV-1) envelope glycoprotein gp120 V3 glycan supersite is a major site of immune vulnerability located on the outer domain of the viral envelope (Kong et al., 2013, Nature Structural & Molecular Biology). This supersite is characterized by a cluster of conserved N-linked glycans, most notably at position N332, and the protein backbone at the base of the V3 variable loop (Sok et al., 2016, Science Translational Medicine). Biologically, gp120 mediates viral entry by binding to host CD4 receptors and coreceptors, a process that is essential for the HIV-1 life cycle and the progression of AIDS (Sanders & Moore, 2021, Nature Reviews Immunology). In clinical applications, this site is the target of potent broadly neutralizing antibodies (bNAbs) like 10-1074 and PGT121, which are being developed for both HIV-1 treatment and prevention (Caskey et al., 2017, Nature Medicine). These antibodies work by sterically hindering viral attachment and fusion, effectively neutralizing the virus across diverse global strains (Gilead Sciences, 2023). Despite its conservation, the site is subject to viral escape through glycan shifting or loss, which remains a significant challenge for long-term therapeutic efficacy.

Other names

N332 glycan supersiteV3-base glycan epitopePGT121-like epitopeHigh-mannose patch

Broadly neutralizing antibodies (bNAbs) target this site to inhibit viral entry by sterically blocking the interaction of gp120 with host cell receptors (CD4 and CCR5/CXCR4) and by promoting the clearance of free virions and infected cells through Fc-mediated effector functions (Sok et al., 2016, Science Translational Medicine; Caskey et al., 2017, Nature Medicine).